We further compared EVs according to IPI score for AIDS-NHL patients with DLBCL tumor subtype, and found that the group with IPI scores between 2–3 had significantly higher EVs bearing PD-L1, CD40, CD40L or TNF-RII compared to the group with an IPI score between 0 and 1 (Fig. 4). This evidence concerns the gene CD40 and non-Hodgkin lymphoma.